PDS Biotechnology

All the posts published.

PDS Biotechnology Reports Final Results for the Full Year 2020 & Business Update

Mar 18, 2021
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS Biotechnology Reports Final Results for the Full Year 2020 & Business Update   London, UK – 18 March 2021 – NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) announced its [...]

PDS COVID-19 Vaccine Commercialisation Update

Mar 11, 2021
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company") PDS COVID-19 Vaccine Commercialisation Update c. $60m Funding Commitment by Brazilian government for Clinical Development and Commercialisation of PDS Consortium’s COVID-19 Vaccine London, UK – 11 March 2021 – NetScientific plc (AIM: NSCI), the life sciences and sustainability technology investment and commercialisation Group, announces that PDS Biotech’s [...]

PDS COVID-19 Vaccine Commercialisation Update

Feb 23, 2021
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific", the “Group” or the "Company")   PDS COVID-19 Vaccine Commercialisation Update   Blanver joins PDS-Farmacore COVID-19 Vaccine Consortium   PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine   London, UK – 23 February 2021 – NetScientific plc (AIM: NSCI), the life sciences and sustainability [...]

PDS Phase II Trial Update & Restoration of Trading

Feb 3, 2021
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company")   PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute   Restoration of Trading   The National Cancer Institute’s (NCI) Phase II clinical study of PDS Biotech’s PDS0101 for HPV-associated cancers has achieved its preliminary objective response. Full enrollment [...]

PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine

Dec 21, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine Versamune® T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine   London, UK – 21 December 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, [...]

PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

Nov 11, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency London, UK – 11 November 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces [...]

PDS Biotech launch Merck Trials

Nov 10, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company")   PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients London, UK – 09 November 2020 – NetScientific [...]

PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101

Oct 27, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer London, UK – 26 October 2020 – NetScientific plc (AIM: NSCI), the life sciences and technology investment and commercialisation company, announces that it its portfolio company PDS Biotechnology Corporation ("PDS") [...]

PDS Announces Closing of $19m Offering

Aug 14, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) yesterday announced the closing of its previously announced [...]

PDS Announces Pricing of $16.5m Common Stock Offer

Aug 12, 2020
-
News, PDS Biotechnology, RNS Announcements
NetScientific plc ("NetScientific" or the "Company") PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) yesterday finalised pricing of its previously announced underwritten public offering which consisted of 6,000,000 shares of [...]
PDS Biotechnology Archives - NetScientific